Tandem Diabetes (TNDM) reported Q1 EPS of ($0.23), $0.16 worse than the analyst estimate of ($0.07). Revenue for the quarter came in at $175.9 million versus the consensus estimate of $168.43 million.
GUIDANCE:
Tandem Diabetes sees FY2022 revenue of $850-865 million, versus the consensus of $846.5 million.